Personalized Cancer Vaccines Using Tumor Neoantigens

Abstract

Personalized cancer vaccines targeting tumor-specific neoantigens represent an important advance in precision oncology. Neoantigens are peptide sequences created by tumor-specific genomic alterations and are absent from healthy tissues, making them attractive targets for selective immune activation. Advances in next-generation sequencing, computational antigen prediction, messenger RNA and synthetic long-peptide manufacturing, and immune monitoring have made individualized vaccine development increasingly feasible. Early clinical studies in melanoma, pancreatic ductal adenocarcinoma, glioblastoma, and other solid tumors suggest that personalized vaccines can induce broad and durable T-cell responses, particularly when combined with immune checkpoint inhibitors. However, clinical benefit remains variable and is influenced by tumor mutational burden, antigen presentation, clonal heterogeneity, immunosuppressive signaling, manufacturing time, and the clinical condition of the patient. This review summarizes the biological rationale, disease burden, clinical implementation, diagnostic requirements, treatment strategies, emerging evidence, and guideline-relevant considerations for neoantigen-directed cancer vaccination.

Introduction

Cancer immunotherapy has progressed from nonspecific immune stimulation to therapies designed around the molecular characteristics of an individual tumor. Personalized cancer vaccines using tumor neoantigens are a leading example of this transition. Unlike conventional vaccines directed against infectious organisms or shared tumor-associated antigens, neoantigen vaccines target abnormal peptides generated by somatic mutations, gene fusions, abnormal RNA processing, or other tumor-specific alterations. Because these peptides are generally not present during normal thymic selection, they may be recognized as non-self by T lymphocytes with comparatively limited risk of central immune tolerance.

The therapeutic objective is to present selected neoantigens in an immunogenic context, expand tumor-reactive CD4-positive and CD8-positive T cells, promote trafficking into the tumor microenvironment, and establish immunologic memory. Personalized vaccination is usually integrated with surgery, chemotherapy, radiotherapy, or immune checkpoint blockade rather than used as an isolated intervention. Its development requires a multidisciplinary workflow involving tissue acquisition, sequencing, bioinformatic prediction, clinical manufacturing, quality control, and serial immune assessment. For clinicians, the principal question is not only whether a vaccine can generate an immune response, but whether that response can prevent recurrence, delay progression, and improve survival without unacceptable treatment delays or toxicity.

Epidemiology / Disease Burden

Cancer remains a leading cause of morbidity and mortality worldwide, with millions of new diagnoses and cancer-related deaths annually. The disease burden is especially substantial in malignancies that frequently recur after apparently curative treatment, including melanoma, pancreatic cancer, colorectal cancer, non-small-cell lung cancer, ovarian cancer, and selected central nervous system tumors. Although surgery and systemic therapy can produce durable remission in some patients, microscopic residual disease and the emergence of resistant subclones remain major causes of treatment failure.

The potential relevance of neoantigen vaccination differs among tumor types. Tumors with high mutational burden, such as melanoma and smoking-associated lung cancer, may generate more candidate neoantigens. Conversely, tumors with lower mutational burden can still harbor highly immunogenic driver mutations or fusion-derived antigens. The number of mutations alone does not determine clinical responsiveness. Antigen processing, human leukocyte antigen genotype, clonality, expression level, and the immune landscape of the tumor are equally important. Consequently, epidemiologic selection for vaccination is likely to evolve toward molecular and immunologic criteria rather than relying solely on histologic diagnosis.

Pathophysiology

Somatic mutations can alter the amino acid sequence of proteins expressed by malignant cells. After intracellular processing, mutant peptides may be loaded onto major histocompatibility complex molecules and displayed on the tumor-cell surface. If a peptide binds effectively to a patient-specific human leukocyte antigen molecule and is recognized by a T-cell receptor, it can serve as a neoantigen. Frameshift mutations, splice-site alterations, gene fusions, and mutations in expressed coding regions may be particularly valuable sources of candidate targets.

Vaccine platforms include synthetic long peptides, messenger RNA, DNA constructs, viral vectors, and cellular delivery systems. Long peptides and messenger RNA can stimulate antigen presentation by professional antigen-presenting cells, including dendritic cells, and support both helper and cytotoxic T-cell responses. Innate immune activation is often necessary for effective priming, but excessive inflammation can cause toxicity or premature clearance of the therapeutic material. Checkpoint inhibitors directed against programmed cell death protein 1, programmed death-ligand 1, or cytotoxic T-lymphocyte-associated antigen 4 may enhance vaccine activity by reversing inhibitory signaling within the tumor microenvironment.

Several biological barriers limit efficacy. Tumors may lose the mutated gene, reduce antigen expression, impair beta-2 microglobulin or antigen-processing machinery, or alter human leukocyte antigen expression. Intratumoral heterogeneity can also result in targeting of a subclone while leaving other malignant populations unaffected. Regulatory T cells, myeloid-derived suppressor cells, tumor-associated macrophages, hypoxia, abnormal vasculature, and immunosuppressive cytokines can prevent activated lymphocytes from reaching or eliminating tumor cells.

Risk Factors

The risk factors relevant to patients considered for neoantigen vaccination are primarily those associated with the underlying cancer and its recurrence. Tobacco exposure, ultraviolet radiation, chronic inflammation, inherited cancer predisposition, obesity, viral infection, and occupational carcinogen exposure may contribute to mutational burden or tumor development depending on the cancer type. Prior systemic treatment can alter immune competence, lymphocyte reserves, and the composition of residual disease.

Patient-specific factors also affect feasibility and safety. Poor performance status, uncontrolled infection, active autoimmune disease, chronic immunosuppressive therapy, severe organ dysfunction, and inadequate tissue availability may limit eligibility. A high predicted neoantigen count does not guarantee benefit, while a low count does not automatically exclude a patient. Clinical judgment should incorporate disease stage, recurrence risk, available standard treatment, expected manufacturing interval, tumor accessibility, and the patient’s willingness to undergo intensive monitoring.

Clinical Features

Neoantigen vaccination is not associated with a unique clinical syndrome because the presenting features arise from the underlying malignancy. Patients may be asymptomatic after resection and receive vaccination as adjuvant therapy for molecularly high-risk disease, or they may have measurable metastatic cancer in an investigational treatment setting. Clinical manifestations therefore range from localized symptoms to constitutional decline, pain, organ dysfunction, neurologic deficits, respiratory compromise, or complications caused by tumor burden.

Potential vaccine-related adverse effects are generally immune-mediated or inflammatory. Injection-site pain, fatigue, fever, chills, myalgia, and transient malaise are common considerations. When vaccination is combined with checkpoint blockade, immune-related events such as dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, or myocarditis may occur. Differentiating tumor progression, infection, cytokine-related symptoms, and immune toxicity requires careful clinical assessment and appropriate laboratory and imaging evaluation.

Diagnosis

Development of a personalized vaccine begins with confirmation of the cancer diagnosis, accurate staging, and acquisition of high-quality tumor tissue with matched normal DNA, usually from blood. Broad next-generation sequencing may identify single-nucleotide variants, insertions and deletions, copy-number changes, structural variants, and gene fusions. RNA sequencing can determine whether candidate mutations are transcribed and may improve prioritization of expressed targets.

Bioinformatic pipelines predict peptide binding to the patient’s human leukocyte antigen molecules and rank candidates according to mutation clonality, gene expression, binding affinity, processing probability, and similarity to normal peptides. Because prediction algorithms are imperfect, candidate selection should be supported by orthogonal laboratory or immunologic testing when feasible. Baseline evaluation commonly includes complete blood counts, renal and hepatic function, assessment of infectious risks, imaging for measurable disease, and review of prior therapies. Serial circulating tumor DNA, tumor biopsies, T-cell receptor sequencing, and cytokine studies may help assess pharmacodynamic activity, although these tools are not uniformly standardized for routine care.

Treatment & Management

Management is individualized and should be conducted within a multidisciplinary oncology program or a rigorously supervised clinical trial. Surgery remains essential when resection is clinically appropriate. In the adjuvant setting, tumor sequencing may be performed soon after surgery so that vaccine production can proceed during recovery or planned systemic treatment. In advanced disease, vaccination must be balanced against the need for therapies with established rapid response rates. Manufacturing timelines are clinically important because disease progression during production can make a completed vaccine unusable.

Vaccines may be administered as a series of priming and booster doses. The platform, dose, schedule, adjuvant strategy, and combination therapy depend on the trial or regulatory framework. Checkpoint inhibition is a common combination approach because vaccine-induced T cells may be functionally restrained by the tumor microenvironment. Conventional chemotherapy or radiotherapy may also influence antigen release, immunogenic cell death, and immune-cell recruitment, but treatment sequencing requires careful consideration of lymphocyte suppression and toxicity.

Response assessment should use standard radiographic criteria while recognizing that immune therapies can produce delayed responses or transient inflammatory enlargement. Pseudoprogression should not be assumed automatically, particularly in patients with clinical deterioration. Management of immune-related toxicity follows established organ-specific algorithms, including treatment interruption, corticosteroids, and additional immunosuppression when indicated. Vaccination should complement rather than replace evidence-based supportive care, symptom control, genetic counseling when appropriate, and psychosocial support.

Recent Advances / Emerging Therapies

Recent clinical studies have demonstrated that individualized messenger RNA and synthetic peptide vaccines can generate polyfunctional T-cell responses against multiple neoantigens. In melanoma, early randomized and single-arm studies have reported encouraging recurrence-related outcomes when personalized vaccination is combined with programmed death protein 1 blockade. Studies in pancreatic cancer have shown that vaccine-induced T-cell responses may be associated with delayed recurrence in selected patients, although larger controlled trials are needed. Research in colorectal cancer, glioblastoma, renal cell carcinoma, and lung cancer is evaluating whether vaccine strategies can overcome traditionally immunologically resistant tumor environments.

Technological progress is focused on faster manufacturing, improved antigen ranking, and more reliable identification of immunogenic targets. Machine-learning models increasingly integrate genomic, transcriptomic, proteomic, and immunopeptidomic data. Multi-antigen designs seek to reduce immune escape by targeting clonal and subclonal mutations simultaneously. Off-the-shelf vaccines directed against recurrent driver alterations may eventually complement fully individualized products, although shared targets must demonstrate adequate tumor specificity and population coverage.

Additional approaches include vaccines combined with personalized adoptive T-cell therapy, oncolytic viruses, intratumoral immune agonists, radiotherapy, and agents that remodel the tumor stroma or myeloid compartment. Minimal residual disease detection using circulating tumor DNA may help identify patients most likely to benefit from adjuvant vaccination and may provide an early endpoint for treatment adaptation. Nevertheless, surrogate biomarkers require prospective validation before they can replace recurrence-free or overall survival outcomes.

Guideline Recommendations

At present, personalized neoantigen vaccines should generally be considered investigational and offered primarily through well-designed clinical trials, institutional precision-oncology programs, or approved regulatory pathways where available. Standard-of-care therapy should not be delayed solely to obtain a vaccine unless the clinical protocol establishes that the expected benefit justifies the manufacturing interval. Patient selection should include pathologic confirmation, appropriate staging, sufficient tumor material, matched normal sequencing, performance-status assessment, organ-function testing, and a transparent discussion of uncertain benefit.

Clinical teams should use validated sequencing and bioinformatic workflows, maintain chain-of-identity and product-quality controls, and document immune and clinical outcomes prospectively. Combination with checkpoint inhibition should follow evidence from the relevant disease setting and should include education about immune-related adverse events. Multidisciplinary review by medical oncology, surgical oncology, pathology, molecular genetics, bioinformatics, pharmacy, and research personnel is recommended. Participation in registries and harmonized reporting systems will be important for determining which neoantigen characteristics, vaccine platforms, and treatment sequences produce reproducible clinical benefit.

Conclusion

Personalized cancer vaccines using tumor neoantigens provide a rational strategy for directing adaptive immunity toward molecular abnormalities unique to an individual patient’s cancer. Their clinical promise is supported by improved sequencing, antigen prediction, manufacturing, and early evidence of durable T-cell responses, particularly when combined with immune checkpoint blockade. Major challenges remain, including tumor heterogeneity, immune escape, immunosuppressive microenvironments, production time, inconsistent biomarker performance, and the need for definitive survival data. For current practice, these vaccines are best delivered within clinical trials and specialized multidisciplinary programs, with standard treatment maintained whenever clinically necessary. Continued integration of genomics, immunology, circulating tumor DNA, and prospective clinical evidence will determine whether neoantigen vaccination becomes a broadly applicable component of precision oncology.